Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01562-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Si-Yang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Nitroimidazoles, Oxazolidinones. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation (GF), Tres Cantos Open Lab Foundation, Orchid Grant Agreement.
Abstract (Originalsprache)
The combination of bedaquiline, pretomanid, and linezolid (BPaL) has become a preferred regimen for treating multidrug- and extensively drug-resistant tuberculosis (TB). However, treatment-limiting toxicities of linezolid and reports of emerging bedaquiline and pretomanid resistance necessitate efforts to develop new short-course oral regimens. We recently found that the addition of GSK2556286 increases the bactericidal and sterilizing activity of BPa-containing regimens in a well-established BALB/c mouse model of tuberculosis. Here, we used this model to evaluate the potential of new regimens combining bedaquiline or the more potent diarylquinoline TBAJ-587 with GSK2556286 and the DprE1 inhibitor TBA-7371, all of which are currently in early-phase clinical trials. We found the combination of bedaquiline, GSK2556286, and TBA-7371 to be more active than the first-line regimen and nearly as effective as BPaL in terms of bactericidal and sterilizing activity. In addition, we found that GSK2556286 and TBA-7371 were as effective as pretomanid and the novel oxazolidinone TBI-223 when either drug pair was combined with TBAJ-587 and that the addition of GSK2556286 increased the bactericidal activity of the TBAJ-587, pretomanid, and TBI-223 combination. We conclude that GSK2556286 and TBA-7371 have the potential to replace pretomanid, an oxazolidinone, or both components, in combination with bedaquiline or TBAJ-587.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
- Global Health Medicines R&D, GlaxoSmithKline R&D Limited, Tres Cantos, Madrid, Spain.
ORCID-Profile: David Barros-Aguirre, Eric L Nuermberger
Förderung
- Bill and Melinda Gates Foundation (GF)
- Tres Cantos Open Lab Foundation
- Orchid Grant Agreement
- European Union 7th Framework Program
Zitieren
APA
Li, S. Y., Tyagi, S., Soni, H., Betoudji, F., Converse, P. J., Mdluli, K., Upton, A. M., Fotouhi, N., Barros-Aguirre, D., Ballell, L., Jimenez-Navarro, E., & Nuermberger, E. L. (2024). Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01562-23
Vancouver
Li SY, Tyagi S, Soni H, Betoudji F, Converse PJ, Mdluli K, et al. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01562-23
BibTeX
@article{Li2024,
author = {Li, Si-Yang and Tyagi, Sandeep and Soni, Heena and Betoudji, Fabrice and Converse, Paul J and Mdluli, Khisimuzi and Upton, Anna M and Fotouhi, Nader and Barros-Aguirre, David and Ballell, Lluís and Jimenez-Navarro, Elena and Nuermberger, Eric L},
title = {Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01562-23}
}
EUVIMED